PT2663579T - Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização - Google Patents

Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização

Info

Publication number
PT2663579T
PT2663579T PT127347334T PT12734733T PT2663579T PT 2663579 T PT2663579 T PT 2663579T PT 127347334 T PT127347334 T PT 127347334T PT 12734733 T PT12734733 T PT 12734733T PT 2663579 T PT2663579 T PT 2663579T
Authority
PT
Portugal
Prior art keywords
protein
methods
same
antibodies against
therapeutic antibodies
Prior art date
Application number
PT127347334T
Other languages
English (en)
Inventor
J Kipps Thomas
F Widhopf Ii George
Cui Bing
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46507696&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2663579(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of PT2663579T publication Critical patent/PT2663579T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT127347334T 2011-01-14 2012-01-13 Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização PT2663579T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161433043P 2011-01-14 2011-01-14

Publications (1)

Publication Number Publication Date
PT2663579T true PT2663579T (pt) 2017-07-28

Family

ID=46507696

Family Applications (2)

Application Number Title Priority Date Filing Date
PT127347334T PT2663579T (pt) 2011-01-14 2012-01-13 Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
PT191929736T PT3604339T (pt) 2011-01-14 2012-01-13 Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT191929736T PT3604339T (pt) 2011-01-14 2012-01-13 Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos

Country Status (9)

Country Link
US (7) US9217040B2 (pt)
EP (4) EP3885366A3 (pt)
CA (3) CA2858350A1 (pt)
DK (3) DK2663579T3 (pt)
ES (3) ES2758533T3 (pt)
HU (2) HUE035281T2 (pt)
PL (2) PL2663579T3 (pt)
PT (2) PT2663579T (pt)
WO (1) WO2012097313A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079902A2 (en) 2009-12-18 2011-07-07 Biolnvent International Ab Biological materials and uses thereof
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
EP3838923B1 (en) * 2012-08-24 2024-05-01 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
AU2015295349B2 (en) * 2014-07-29 2020-09-24 Cellectis ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
EP3194432B1 (en) 2014-07-31 2019-04-10 Cellectis Ror1 specific multi-chain chimeric antigen receptor
AU2015310897B2 (en) 2014-09-04 2020-03-19 Cellectis Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
KR20160132534A (ko) 2015-05-11 2016-11-21 경북대학교병원 ＲＯＲα 활성조절제를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
FI3298033T4 (fi) 2015-05-18 2023-09-22 Tcr2 Therapeutics Inc Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
EP3842072A1 (en) * 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies
WO2016185035A1 (en) 2015-05-20 2016-11-24 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
BR112018014615A2 (pt) 2016-01-20 2018-12-11 The Scripps Research Institute composições de anticorpo para ror1 e métodos relacionados
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
WO2018014001A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
AU2017341048A1 (en) 2016-10-07 2019-05-23 TCR2 Therapeutics Inc. Compositions and methods for T-cell receptors reprogramming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CA3067829A1 (en) 2017-06-23 2018-12-27 VelosBio Inc. Ror1 antibody immunoconjugates
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
JP2021502330A (ja) 2017-10-20 2021-01-28 フレッド ハッチンソン キャンサー リサーチ センター Ｔｉｇｉｔおよび／またはｃｄ１１２ｒを標的とするか、またはｃｄ２２６過剰発現を含む、組成物および免疫治療の方法
US10905750B2 (en) 2017-11-10 2021-02-02 Donald J. Davidson GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
CN112041335A (zh) 2018-02-26 2020-12-04 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的组合物和方法
CA3093568A1 (en) * 2018-03-09 2019-09-12 The Regents Of The University Of California Combination treatment of chemoresistant cancers
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
JPWO2020026987A1 (ja) * 2018-08-01 2021-08-19 国立大学法人東海国立大学機構 抗ｒｏｒ１モノクローナル抗体およびその機能的断片、遺伝子、薬剤デリバリー組成物、並びに、医薬組成物
EP4306540A1 (en) 2021-03-09 2024-01-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Ror1 binding protein and use thereof
CA3218527A1 (en) 2021-06-02 2022-12-08 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody drug conjugate, and preparation method therefor and use thereof
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN113980133B (zh) * 2021-10-29 2022-09-13 叶鑫淼 抗体及其在抗肿瘤中的应用
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
US5169836A (en) 1988-11-10 1992-12-08 Trustees Of The University Of Penna. Inhibitors of platelet binding
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9108652D0 (en) 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5843749A (en) 1991-07-26 1998-12-01 Regeneron Pharmaceuticals, Inc. Ehk and Ror tyrosine kinases
DE69228247T2 (de) 1991-08-10 1999-07-08 Medical Res Council Behandlung von Zellpopulationen
CA2105618C (en) 1992-09-07 2009-11-03 Kazuyasu Nakamura Humanized antibodies to ganglioside gm2
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5977316A (en) 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
ATE208403T1 (de) 1995-05-26 2001-11-15 Merck Patent Gmbh Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
CA2223577A1 (en) 1995-06-07 1996-12-19 Connaught Laboratories Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
EP0918858A1 (en) 1996-05-10 1999-06-02 Biogen, Inc. Common gamma chain blocking agents
ATE253593T1 (de) 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
ES2352082T3 (es) 1997-11-21 2011-02-15 Merck Serono Biodevelopment Polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección.
US7041490B1 (en) 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
US6562958B1 (en) 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
AU756960B2 (en) 1998-06-26 2003-01-30 Iowa State University Research Foundation Inc. Materials and methods for the alteration of enzyme and acetyl CoA levels in plants
BR9915543A (pt) 1998-10-16 2001-08-14 Fraunhofer Ges Forschung Resistência a doenças por plantas mediada por patogenicidas moleculares
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
NZ530573A (en) 1999-03-11 2005-09-30 Genesis Res & Dev Corp Ltd Compositions and methods for the modification of gene transcription
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6753314B1 (en) 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
DE50015293D1 (de) 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
US20060242729A1 (en) 1999-07-30 2006-10-26 Cahoon Edgar B Polynucleotides encoding proteins involved in plant metabolism
GB9918788D0 (en) 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
DE19946142A1 (de) 1999-09-27 2001-03-29 Bundesrepublik Deutschland Let Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren
US20020034784A1 (en) 1999-10-27 2002-03-21 John Bertin Novel molecules of the card-related protein family and uses thereof
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US20030235584A1 (en) 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
US20030092091A1 (en) 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies
US6833447B1 (en) 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
EP1392859B1 (en) 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20140072980A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20140072979A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
BR0207068A (pt) 2001-01-26 2004-12-21 Inhibitex Inc Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AU2002302919A1 (en) 2001-02-22 2002-10-03 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7282336B2 (en) 2001-07-18 2007-10-16 Bionomics Limited Method of diagnosing epilepsy
KR100464926B1 (ko) 2001-09-14 2005-01-05 한국과학기술연구원 ＨＩＶ-1 ｇｐ41의 Ｎ-말단에 특이적으로 결합하는 항체
US7361478B2 (en) 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DK1495055T3 (da) 2002-04-18 2013-11-11 Genencor Int Produktion af funktionelle antistoffer i filamentøse svampe
GB0210783D0 (en) 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US8344211B2 (en) 2008-08-13 2013-01-01 Ceres, Inc. Plant nucleotide sequences and corresponding polypeptides
US7205450B2 (en) 2003-10-08 2007-04-17 The Regents Of The University Of California DMI1 gene encodes a protein that is required for the early steps of bacterial and fungal symbioses
PE20050925A1 (es) 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
PT2805728T (pt) 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
ES2364147T3 (es) 2004-01-16 2011-08-25 Regeneron Pharmaceuticals, Inc. Polipéptidos de fusión capaces de activar receptores.
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US7608700B2 (en) 2004-03-08 2009-10-27 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding stress-related proteins and uses therefor
EP1735461A4 (en) 2004-04-06 2008-10-29 Univ California ORPHANIC RECEPTOR TYROSINE KINASE AS A TARGET IN BREAST CANCER
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
RU2006145905A (ru) 2004-05-25 2008-06-27 ЭТТЕНЬЮОН, ЭлЭлСи (US) Лиганды, связывающие комплекс активатора плазминогена урокиназного типа (upa) и его рецептора (upar), которые ингибируют последующие взаимодействия upar: идентификация и использование в диагностике или терапии
US7629444B1 (en) 2004-06-15 2009-12-08 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus bovienii strain Xs85831 and uses thereof
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
US7319142B1 (en) 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PT1836225E (pt) 2005-01-06 2012-01-10 Novo Nordisk As Agentes de ligação a kir e métodos de utilização dos mesmos
US8519225B2 (en) 2006-02-10 2013-08-27 Monsanto Technology Llc Identification and use of target genes for control of plant parasitic nematodes
CA2598792A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US8119385B2 (en) 2005-03-04 2012-02-21 Bp Corporation North America Inc. Nucleic acids and proteins and methods for making and using them
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2006138606A2 (en) 2005-06-17 2006-12-28 Arborgen, Llc Cell signaling genes and related methods
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
WO2007051077A2 (en) * 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
WO2008103849A2 (en) 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
ES2541302T3 (es) 2005-11-18 2015-07-17 Glenmark Pharmaceuticals S.A. Anticuerpos anti-integrina alfa2 y sus usos
CA2627446A1 (en) 2005-11-21 2007-05-31 Laboratoires Serono S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
EP2527370A1 (en) 2005-12-21 2012-11-28 Amgen Research (Munich) GmbH Compounds having resistance to soluble CEA
US8075884B2 (en) 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
CA2895745A1 (en) 2006-02-09 2007-08-16 Pioneer Hi-Bred International, Inc. Genes for enhancing nitrogen utilization efficiency in crop plants
EP2639242A3 (en) 2006-03-06 2013-10-16 MedImmune, Inc. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1998807A4 (en) 2006-03-21 2010-02-17 David T Weaver METHODS OF HUMANIZING ANTIBODIES AND HUMANIZED ANTIBODIES THUS OBTAINED
BRPI0708998A2 (pt) 2006-03-21 2011-06-21 Wyeth Corp anticorpo que se liga especificamente ao rage; anticorpo quimérico ou um fragmento de ligação rage do mesmo; anticorpo humanizado ou um fragmento de ligação rage do mesmo; anticorpo humanizado que se liga especificamente ao rage ou um fragmento de ligação rage do mesmo; anticorpo que se liga especificamente ao rage e bloqueia a ligação de um parceiro corporal rage; ácido nucléico isolado; método de tratamento de um indivìduo que tem uma doença ou transtorno relacionado com rage; método de tratamento de sepse ou choque séptico em um indivìduo humano; método de tratamento de listeriose sistêmica em um indivìduo humano; e método de inibir a ligação de um parceiro de ligação rage (rage-bp), o rage em um indivìduo mamìfero
JP5033868B2 (ja) 2006-03-23 2012-09-26 バイオアークティック ニューロサイエンス アーベー 改良型プロトフィブリル選択的抗体及びその使用
US7727525B2 (en) 2006-05-11 2010-06-01 City Of Hope Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
ES2549128T3 (es) 2006-05-19 2015-10-23 Technion Research And Development Foundation Ltd. Proteínas de fusión, usos de las mismas y procesos para producir las mismas
BRPI0712222B1 (pt) 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
AU2007262666B2 (en) 2006-06-22 2013-09-12 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
KR101429783B1 (ko) 2006-07-12 2014-08-18 가부시키가이샤 진 테크노 사이언스 항 인간 α９ 인테그린 항체와 그 용도
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
JP2009274958A (ja) 2006-08-31 2009-11-26 Nara Prefecture 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
ES2902063T3 (es) 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Proteínas de unión a interleucina-13
CN101594883B (zh) 2006-10-12 2018-04-10 中外制药株式会社 使用抗ereg抗体的癌症的诊断和治疗
CL2007003661A1 (es) 2006-12-18 2008-07-18 Genentech Inc Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3.
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
JP5374360B2 (ja) 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
NZ578943A (en) 2007-03-01 2012-09-28 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions
BRPI0809026A2 (pt) 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
CA2685015A1 (en) 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
US7959916B2 (en) 2007-04-23 2011-06-14 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by ERp5
US20100129817A1 (en) 2007-05-03 2010-05-27 Regeneron Pharmaceuticals Inc. Identifying germline competent embryonic stem cells
WO2009017679A2 (en) 2007-07-31 2009-02-05 Merck & Co., Inc. Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
MX349306B (es) 2007-09-21 2017-07-19 Univ California Interferón de objetivo demuestra actividades potentes apoptóticas y antitumorales.
WO2009064854A2 (en) 2007-11-13 2009-05-22 Cogenesys, Inc Humanized antibodies against tl1a
US8309323B2 (en) 2007-11-13 2012-11-13 Synthetic Genomics, Inc. Dimethyloctane as an advanced biofuel
US20130338038A1 (en) 2007-12-21 2013-12-19 Pdl Biopharma, Inc. Method of screening complex protein libraries to identify altered properties
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
US8728803B2 (en) 2008-02-28 2014-05-20 Battelle Energy Alliance, Llc Thermophilic and thermoacidophilic metabolism genes and enzymes from Alicyclobacillus acidocaldarius and related organisms, methods
CA2715212A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
EP2272872A4 (en) 2008-03-21 2011-04-06 Hayashibara Biochem Lab MONOCLONAL ANTIBODIES SPECIFICALLY RECOGNIZING THE ALPHA 8 SUBTYPE OF THE HUMAN ALPHA INTERFERON AND ASSOCIATED MUTANT PROTEIN
PE20091674A1 (es) 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
JP2010014691A (ja) 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
WO2010008069A1 (ja) 2008-07-18 2010-01-21 国立大学法人名古屋大学 細胞増殖阻害剤
NZ590330A (en) 2008-07-21 2012-08-31 Immunomedics Inc Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
BR122021014158B1 (pt) 2008-08-18 2022-08-16 Evogene Ltd. Método para aumentar a eficiência de uso do nitrogênio, e/ou tolerância à deficiência de nitrogênio de uma planta
NZ592436A (en) 2008-11-06 2012-10-26 Glenmark Pharmaceuticals Sa Treatment with anti-alpha2 integrin antibodies
AU2010208637A1 (en) 2009-01-29 2011-08-04 Abbvie Inc. IL-1 binding proteins
PE20160651A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
EP2246364A1 (en) 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
US8753631B2 (en) 2009-05-01 2014-06-17 New York University Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
WO2010138184A2 (en) 2009-05-27 2010-12-02 Synageva Biopharma Corp. Avian derived antibodies
CN102574915B (zh) 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
IN2012DN02737A (pt) 2009-09-01 2015-09-11 Abbott Lab
US8163283B2 (en) 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
WO2011079902A2 (en) 2009-12-18 2011-07-07 Biolnvent International Ab Biological materials and uses thereof
KR20120102125A (ko) 2009-12-18 2012-09-17 사노피 Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
US8951532B2 (en) 2010-01-25 2015-02-10 Alere Scarborough, Inc. A25 bacteriophage lysin
WO2011094259A2 (en) 2010-01-28 2011-08-04 Glaxo Group Limited Cd127 binding proteins
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2011215750A1 (en) 2010-02-11 2012-08-23 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-CD200 antibodies
CA3027824A1 (en) 2010-02-23 2011-09-01 Sanofi Anti-alpha2 integrin antibodies and their uses
PL2539366T3 (pl) 2010-02-26 2018-06-29 Bioarctic Neuroscience Ab Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiach
EP2542590B2 (en) 2010-03-05 2020-04-01 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CN102190728B (zh) 2010-03-17 2014-07-02 永卓博济(上海)生物医药技术有限公司 一种人源化抗cd20单克隆抗体
US8468130B2 (en) 2010-04-02 2013-06-18 Skyfire Labs, Inc. Assisted hybrid mobile browser
EP3085387A1 (en) 2010-04-26 2016-10-26 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
CN101928347B (zh) 2010-05-05 2013-03-27 上海海抗中医药科技发展有限公司 抗癌胚抗原抗体及其应用
KR20130108104A (ko) 2010-06-03 2013-10-02 아브락시스 바이오사이언스, 엘엘씨 말초혈 ｓｐａｒｃ 결합 항체와 이들의 용도
EP2580240B1 (en) 2010-06-14 2018-11-28 Lykera Biomed S.A. S100a4 antibodies and therapeutic uses thereof
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
WO2012012695A2 (en) 2010-07-23 2012-01-26 Fred Hutchinson Cancer Research Center A method for the treatment of obesity
NZ606880A (en) 2010-08-27 2015-01-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
DK3327040T3 (da) 2010-09-21 2021-09-20 Altor Bioscience Corp Multimeriske opløselige il-15-fusionsmolekyler og fremgangsmåder til at fremstille og anvende samme
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
ES2718849T3 (es) 2010-11-24 2019-07-04 Lexicon Pharmaceuticals Inc Anticuerpos contra notum pectinacetilesterasa
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
CA2821976A1 (en) 2010-12-21 2012-09-13 Abbvie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
CA2827787A1 (en) 2011-03-30 2012-10-04 Boehringer Ingelheim International Gmbh Anticoagulant antidotes
EP2699253B1 (en) 2011-04-21 2018-03-28 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
JP5944994B2 (ja) 2011-08-12 2016-07-05 オメロス コーポレーション 抗ｆｚｄ１０モノクローナル抗体およびそれらの使用方法
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
EP2776470A2 (en) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Antibodies specific for trop-2 and their uses
AP2014007571A0 (en) 2011-11-16 2014-04-30 Boehringer Ingelheim Int Anti IL-36R antibodies
SG11201402619VA (en) 2011-11-23 2014-10-30 Igenica Biotherapeutics Inc Anti-cd98 antibodies and methods of use thereof
WO2013078977A1 (zh) 2011-11-28 2013-06-06 厦门松霖科技有限公司 一种面盖隐藏式花洒
EP2617319A1 (en) 2012-01-17 2013-07-24 Braun GmbH Head portion and handle portion of an oral care device
PL2812443T3 (pl) 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
DK2822575T3 (da) 2012-03-03 2020-06-15 Immungene Inc Manipulerede, muterede antistof-interferon-fusionsmolekyler
CN104718290A (zh) 2012-07-24 2015-06-17 Bp北美公司 木糖异构酶及其用途
CN103792364B (zh) 2012-10-31 2016-06-08 张宝弘 用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
TW202206465A (zh) 2012-11-14 2022-02-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9068204B2 (en) 2013-03-15 2015-06-30 The United States Of America, As Represented By The Secretary Of Agriculture Peptidoglycan hydrolase antimicrobials for eradicating lactobacilli that contaminate and reduce ethanol yields in biofuel fermentation
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CN107011441B (zh) 2013-09-13 2020-12-01 百济神州(广州)生物科技有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
MX2016007654A (es) 2013-12-11 2017-08-15 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
ES2754209T3 (es) 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition

Also Published As

Publication number Publication date
EP3885366A2 (en) 2021-09-29
EP3604339A1 (en) 2020-02-05
US20130273073A1 (en) 2013-10-17
US10900973B2 (en) 2021-01-26
US20210208158A1 (en) 2021-07-08
DK2663579T3 (en) 2017-07-31
HUE053720T2 (hu) 2021-07-28
CA2858350A1 (en) 2013-07-19
US20180348232A1 (en) 2018-12-06
EP2663579A4 (en) 2014-09-17
CA2981662A1 (en) 2013-07-19
US11536727B2 (en) 2022-12-27
PL2663579T3 (pl) 2017-09-29
PL3604339T3 (pl) 2021-12-27
EP3252076B1 (en) 2019-09-04
EP2663579B1 (en) 2017-04-26
HUE035281T2 (en) 2018-05-02
EP2663579A2 (en) 2013-11-20
US20200309785A1 (en) 2020-10-01
WO2012097313A2 (en) 2012-07-19
US20170248585A1 (en) 2017-08-31
PT3604339T (pt) 2021-04-13
CA2981662C (en) 2019-02-05
US20230341412A1 (en) 2023-10-26
CA3027071A1 (en) 2013-07-19
US9523695B2 (en) 2016-12-20
DK3252076T3 (da) 2019-12-02
US10627409B2 (en) 2020-04-21
EP3885366A3 (en) 2021-12-29
EP3252076A1 (en) 2017-12-06
ES2634098T3 (es) 2017-09-26
US20160097776A1 (en) 2016-04-07
WO2012097313A3 (en) 2013-01-10
DK3604339T3 (da) 2021-04-12
ES2758533T3 (es) 2020-05-05
US9933434B2 (en) 2018-04-03
US9217040B2 (en) 2015-12-22
ES2865068T3 (es) 2021-10-14
EP3604339B1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
PT3604339T (pt) Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos
HK1255608A1 (zh) 抗htra1抗體及使用方法
HK1199892A1 (en) Modified mini-hepcidin peptides and methods of using thereof
HK1201843A1 (en) Anti-polyubiquitin antibodies and methods of use
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
ZA201308022B (en) Anti-cd40 antibodies and methods of use
EP2771694A4 (en) MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
EP2663647A4 (en) POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
GB201114858D0 (en) Anti-nerve growth factor antibodies and methods of using the same
ZA201400562B (en) Axmi205 variant proteins and methods for their use
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
EP2558496A4 (en) ANTIBODIES TO POLYUBIQUITINE AND METHOD FOR THEIR USE
EP3210997C0 (en) MEANS AND METHOD FOR EXPRESSING AND SECRETING PEPTIDES AND PROTEINS
EP2663330A4 (en) ANTIBODIES TO TLR4 AND METHOD FOR THEIR USE
HK1209432A1 (en) Anti-jagged antibodies and methods of use
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
EP2785742A4 (en) ANTI-KDR ANTIBODIES AND METHOD OF USE THEREOF
EP2670436A4 (en) FOXC1 ANTIBODIES AND METHOD FOR THEIR USE